TRIM33 and dermatomyositis: Two patients had anti-TIF1γ antibodies (typically associated with dermatomyositis and CAM), neither of whom had a rash, although one had locally advanced bladder/prostate cancer, resected 1 month prior to anti-HMGCR testing.